Last updated on October 2018

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Asthma
  • Age: Between 18 - 75 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Male or female subjects aged 18 and 75 years who have signed an Informed Consent form prior to initiation of any study-related procedure.
  • A diagnosis of asthma as defined in the GINA Report, 2016, documented for at least 1 year prior to screening.
  • Subjects with poorly controlled or uncontrolled asthma evidenced by a score at the Asthma Control Questionnaire 7 (ACQ-7) 1.5 (this criterion must be met at screening and at randomization visits).
  • Subjects with a pre-bronchodilator FEV1 50% and <85% of their predicted normal value, after appropriate washout from bronchodilators, at the screening and randomization visits.
  • Subjects with a positive response to a reversibility test at screening (pre - post BD), within 1 year prior to or at screening defined as FEV112% and 200mL over baseline within 30 minutes after inhaling 4 puffs of albuterol HFA 90g/actuation.
  • Use of inhaled corticosteroids (low/medium dose according to GINA Report 2016) with or without a LABD for 3 months (stable dose in the last 4 weeks) before screening visit
  • A cooperative attitude and ability to demonstrate correct use of the diary, peak flow meter, and pMDI inhalers.
  • A basal morning (7-10 am) serum cortisol level between 7-28 g/dL at screening (V1).
  • A Body Mass Index: 18.5 BMI <35 kg/m2.

Exclusion Criteria:

  • Pregnant (as evident by a positive urine hCG or serum -hCG test) or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS they are willing to use a highly effective birth control method
  • Subjects who suffer from COPD as defined by the GOLD Report 2017, or are suspected of having Asthma COPD Overlap Syndrome (ACOS) as defined in GINA Report, 2016.
  • Inability to carry out pulmonary lung function testing, to comply with study procedures or with study drug intake.
  • Current smokers or ex-smokers (tobacco, vapor cigarettes, marijuana) with a smoking history of >10 pack-years or having stopped smoking one year or less prior to screening visit.
  • History of life-threatening asthma, clinically significant uncontrolled disease or respiratory infection.
  • An asthma exacerbation requiring oral corticosteroids within 3 months or hospitalization within 6 months prior to screening.
  • Subjects with unresolved bacterial or viral respiratory tract, sinus or middle ear infection affecting asthma status within 2 weeks prior to screening.
  • Subjects who received a vaccination within 2 weeks prior to screening or during the run-in.
  • Subjects with oral candidiasis at screening or at randomization.
  • Subjects with any clinically significant, uncontrolled condition
  • Subjects who have clinically significant cardiovascular condition
  • Subjects who have a clinically significant abnormal 12-lead ECG that results in active medical problem which may impact the safety of the subject according to Investigator's judgement.
  • Subjects whose 12-lead ECG shows Fridericia corrected QT interval (QTcF) >450ms for males or QTcF >470ms for females at screening and randomization visits.
  • Subjects with known intolerance/hypersensitivity or contra-indication to treatment with 2-adrenergic receptor agonists, inhaled corticosteroids or propellant gases/excipients.
  • Subjects with concomitant immunosuppressive therapy, use of oral or injected corticosteroids, anti-IgE, anti-IL5 or other monoclonal or polycolonal antibodies within 12 weeks prior to screening.
  • Use of potent cytochrome P450 3A4 inhibitors and inducers within 4 weeks prior to screening.
  • History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening.
  • Subjects who have received an investigational drug within 1 month or 5 half-lives (whichever is greater) prior to screening visit, or have been previously randomized in this trial, or are currently participating in another clinical trial.
  • Subjects who are mentally or legally incapacitated, or subjects accommodated in an establishment as a result of an official or judicial order.
  • Subjects who have undergone major surgery in the 3 months prior to screening visit or have a planned surgery during the trial.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.